^
    Apply
    Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma (NCT01745588)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    12/01/2012
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    CD34
    |
    dexamethasone • pomalidomide
    Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 (NCT04874194)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    12/17/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    RUNX1
    |
    RUNX1 mutation
    |
    Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)
    Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. (NCT06328179)
    Phase N/A
    Huai'an First People's Hospital
    Recruiting
    Last update posted :
    03/25/2024
    Initiation :
    05/24/2022
    Primary completion :
    12/30/2027
    Completion :
    12/30/2027
    BCL2
    |
    Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)
    New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool (NCT05495854)
    Phase N/A
    Poitiers University Hospital
    Recruiting
    Last update posted :
    09/14/2023
    Initiation :
    02/03/2023
    Primary completion :
    02/03/2024
    Completion :
    02/03/2024
    MSH2
    Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML (NCT00462943)
    Phase 2
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    12/28/2021
    Initiation :
    03/07/2007
    Primary completion :
    08/04/2009
    Completion :
    06/27/2013
    ABL1 • BCR
    |
    Synribo (omacetaxine mepesuccinate)
    Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation (NCT00375219)
    Phase 2
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    11/15/2021
    Initiation :
    09/20/2006
    Primary completion :
    03/23/2010
    Completion :
    06/28/2013
    ABL1 • BCR
    |
    Synribo (omacetaxine mepesuccinate)
    Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia (NCT00450944)
    Phase 1
    Albert Einstein College of Medicine
    Completed
    Last update posted :
    04/14/2021
    Initiation :
    02/22/2006
    Primary completion :
    10/27/2008
    Completion :
    04/01/2010
    CD19 • CD22
    |
    CD19 expression
    |
    Combotox (Imtox19/Imtox22)
    Azacitidine and Homoharringtonine in JMML (NCT04505995)
    Phase N/A
    Fourth Military Medical University
    Recruiting
    Last update posted :
    08/10/2020
    Initiation :
    01/01/2020
    Primary completion :
    01/01/2023
    Completion :
    01/01/2025
    KRAS • NRAS • PTPN11
    |
    KRAS mutation • NRAS mutation • PTPN11 mutation
    |
    azacitidine • Synribo (omacetaxine mepesuccinate)
    An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (MOXE) (NCT03501615)
    Phase N/A
    AstraZeneca
    Approved for marketing
    Last update posted :
    06/29/2020
    BRAF
    |
    Lumoxiti (moxetumomab pasudotox)
    Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (PLAIT) (NCT01829711)
    Phase 3
    MedImmune LLC
    Completed
    Last update posted :
    04/08/2020
    Initiation :
    04/29/2013
    Primary completion :
    05/24/2017
    Completion :
    04/29/2019
    BRAF • CD22
    |
    Lumoxiti (moxetumomab pasudotox)
    HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma (NCT02370160)
    Phase 1/2
    Masonic Cancer Center, University of Minnesota
    Completed
    Last update posted :
    01/13/2020
    Initiation :
    12/21/2015
    Primary completion :
    04/08/2018
    Completion :
    04/08/2018
    CD22
    |
    OXS-1550
    A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia (NCT00586924)
    Phase 1
    MedImmune LLC
    Completed
    Last update posted :
    04/02/2019
    Initiation :
    05/10/2007
    Primary completion :
    05/06/2015
    Completion :
    05/06/2015
    CD22
    |
    CD22 expression
    |
    Lumoxiti (moxetumomab pasudotox)
    Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) (NCT01030536)
    Phase 1/2
    MedImmune LLC
    Completed
    Last update posted :
    04/09/2018
    Initiation :
    02/15/2010
    Primary completion :
    03/04/2013
    Completion :
    03/04/2013
    CD22
    |
    CD22 expression
    |
    Lumoxiti (moxetumomab pasudotox)
    DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma (NCT00889408)
    Phase 1
    Masonic Cancer Center, University of Minnesota
    Completed
    Last update posted :
    12/02/2017
    Initiation :
    12/02/2013
    Primary completion :
    07/21/2014
    Completion :
    07/21/2014
    CD22
    |
    OXS-1550
    CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma (NCT00659425)
    Phase 1
    MedImmune LLC
    Completed
    Last update posted :
    10/02/2017
    Initiation :
    09/01/2008
    Primary completion :
    12/01/2014
    Completion :
    12/01/2014
    CD22
    |
    CD22 positive • CD22 expression
    |
    Lumoxiti (moxetumomab pasudotox)
    Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma (NCT00460109)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Completed
    Last update posted :
    04/18/2017
    Initiation :
    04/01/2008
    Primary completion :
    10/01/2010
    Completion :
    03/01/2011
    ALB
    |
    Rituxan (rituximab) • Ontak (denileukin diftitox)
    Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02556346)
    Phase 1
    Molecular Templates, Inc.
    Withdrawn
    Last update posted :
    03/02/2016
    Initiation :
    11/01/2015
    Primary completion :
    08/01/2016
    Completion :
    12/01/2016
    CD5
    |
    MT-3724